As we recently identified glycolysis- inhibitors as regulators of survivin expression 24, 25 and cancer cells with elevated survivin are strongly glycolytic, we speculated that a combination of SMAC-mimetics with glycolysis-inhibitors might overcome the survivin- induced phenotype. This evidence concerns the gene BIRC5 and cancer.